Quality of life ‐ not measured · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ‐ not reported · systemic lupus erythematosus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to any reason · systemic lupus erythematosus
It is very uncertain whether summary of findings table ‐ Exercise plus usual pharmacological care changes withdrawals due to any reason compared with placebo plus usual pharmacological care (very low certainty).
1 finding from 1 review
Pain · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 18 to 24 months CA · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major neurodevelopmental disability in children aged 3 to 5 years CA · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay · postoperative pain in preterm and term infants
It is very uncertain whether tramadol changes all‐cause mortality during initial hospitalization compared with no treatment or placebo (very low certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · postoperative pain in preterm and term infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants reporting no worse than mild pain by 14 days after start of treatment · adults with cancer‐related pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change much or very much improved · adults with cancer‐related pain
Cannabis‐based medicines probably leads to higher PGIC of much improved or very much improved compared with placebo medication (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in withdrawals due to adverse events compared with placebo medication (moderate certainty).
1 finding from 1 review
Mean pain intensity (Numeric Rating Scale 0–10) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in mean pain intensity (Numeric Rating Scale 0–10) compared with placebo medication (moderate certainty).
1 finding from 1 review
Daily maintenance opioid dosage (mg morphine equivalent) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in daily maintenance opioid dosage (mg morphine equivalent) compared with placebo medication (low certainty).
1 finding from 1 review
Daily breakthrough opioid dosage (mg morphine equivalent) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in daily breakthrough opioid dosage (mg morphine equivalent) compared with placebo medication (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in participants experiencing any serious adverse event compared with placebo medication (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 281 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care probably leads to lower clinical worsening: participants admitted to hospital or deceased at… compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
Quality of life · non‐hospitalised adults with mild COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found